Skip to main content

Table 8 Biodex data (except for walking speed, higher scores indicate less impairment).

From: S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]

  

Baseline

SAMe

Celecoxib

 

Variable

N+

Mean

(SD)

Mean

(SD)

Mean

(SD)

Stdif.

Isometric 60 degrees

Peak flexion

45

66.7

(30.6)

80.2*

(30.0)

77.5*

(29.2)

0.21

Peak extension

45

92.4

(40.8)

116.6*

(52.0)

112.5*

(50.3)

0.19

Isokinetic 60 degrees

Peak flexion

45

40.5

(21.2)

54.8*

(26.5)

52.3*

(20.9)

0.16

Peak extension

45

84.2

(43.5)

107.1*

(43.0)

102.4*

(39.0)

0.24

Average flexion

45

22.2

(16.8)

32.1*

(18.4)

29.9*

(15.2)

0.19

Average extension

45

48.0

(27.5)

64.3*

(28.3)

62.3*

(26.4)

0.14

Isokinetic 180 degrees

Peak flexion

45

30.7

(15.7)

39.0*

(16.3)

37.9*

(15.1)

0.13

Peak extension

45

57.0

(29.5)

72.3*

(31.0)

69.3*

(28.0)

0.19

Average flexion

45

25.3

(27.8)

42.7*

(32.4)

39.3*

(29.3)

0.18

Average extension

45

76.5

(53.0)

109.6*

(56.4)

105.6*

(50.9)

0.14

Walking Speed

42

3.12

(1.52)

2.63*

(0.91)

2.56*

(0.69)

-0.14

  1. Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe. +Sample sizes are less than 57 due to missing data in either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). No statistically significant differences were observed between SAMe and Celecoxib.